Intersect ENT, Inc. (XENT): Price and Financial Metrics

Intersect ENT, Inc. (XENT): $28.24

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

XENT Price/Volume Stats

Current price $28.24 52-week high $28.25
Prev. close $28.24 52-week low $15.92
Day low $28.23 Volume 837,100
Day high $28.25 Avg. volume 351,526
50-day MA $27.80 Dividend yield N/A
200-day MA $27.27 Market Cap 954.91M

XENT Stock Price Chart Interactive Chart >


Intersect ENT, Inc. (XENT) Company Bio


Intersect ENT provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company was founded in 2003 and is based in Menlo Park, California.


XENT Latest News Stream


Event/Time News Detail
Loading, please wait...

XENT Latest Social Stream


Loading social stream, please wait...

View Full XENT Social Stream

Latest XENT News From Around the Web

Below are the latest news stories about Intersect ENT Inc that investors may wish to consider to help them evaluate XENT as an investment opportunity.

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Havens Advisors Llc Buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Sells , ,

New York, NY, based Investment company Havens Advisors Llc (Current Portfolio) buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Rogers Corp, Triple-S Management Corp, sells , , , Cloudera Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Havens Advisors Llc.

Yahoo | January 31, 2022

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

MENLO PARK, Calif., January 25, 2022--Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Yahoo | January 25, 2022

Intersect ENT, Inc. (NASDAQ:XENT) Expected to Announce Quarterly Sales of $37.13 Million

Analysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will post sales of $37.13 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Intersect ENTs earnings, with estimates ranging from $36.53 million to $37.82 million. Intersect ENT reported sales of $28.23 million in the same quarter last year, which would []

Transcript Daily | December 21, 2021

Read More 'XENT' Stories Here

XENT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 39.25%
5-year -15.42%
YTD N/A
2023 N/A
2022 0.00%
2021 19.26%
2020 -8.03%
2019 -11.64%

Continue Researching XENT

Want to see what other sources are saying about Intersect ENT Inc's financials and stock price? Try the links below:

Intersect ENT Inc (XENT) Stock Price | Nasdaq
Intersect ENT Inc (XENT) Stock Quote, History and News - Yahoo Finance
Intersect ENT Inc (XENT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!